TITLE

Activated protein C was cost-effective for prolonging survival in a subgroup of patients with severe sepsis

AUTHOR(S)
Manns, B.J.; Lee, H.; Doig, C.J.; Johnson, D.; Donaldson, C.; Wiedemann, Herbert P.
PUB. DATE
May 2003
SOURCE
ACP Journal Club;May/Jun2003, Vol. 138 Issue 3, p81
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Summarizes a study that investigated whether treatment with recombinant human-activated protein C is more cost-effective than conventional care for prolonging survival in patients with severe sepsis. Characterization of the patients; Main cost and outcome measures; Results of the study.
ACCESSION #
9874878

 

Related Articles

  • Recombinant human activated protein C in severe sepsis. Mann, Henry J. // American Journal of Health-System Pharmacy;2/15/2002, Vol. 59 Issue 4, pS19 

    Protein C, a naturally occurring vitamin K-dependent serine protease in the blood, remains inactive until exposed to the thrombin-thrombomodulin complex. This change between the inactive and active forms occurs constantly in humans and serves to balance the coagulation cascade. APC functions in...

  • Fresh from the pipeline: Drotrecogin alpha (activated). Lebbos, John; Bradsher, Julia; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Jan2003, Vol. 2 Issue 1, p13 

    In November 2001, drotrecogin alpha (activated) (Xigris) became the first drug to be approved by the FDA for the treatment of severe sepsis, a systemic response to infection that kills an estimated 500,000 people each year. Xigris was widely anticipated to be a blockbuster, but it has not yet...

  • Activated Protein C for Sepsis. Mackenzie, Alasdair // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A letter to the editor is presented in response to the article "Activated Protein C for Sepsis," by S. Toussaint et al. published in the December 31, 2009 issue.

  • Activated Protein C for Sepsis. Toussaint, Susanne; Gerlach, Herwig // New England Journal of Medicine;3/25/2010, Vol. 362 Issue 12, p1150 

    A response by Susanne Toussaint and Herwig Gerlach to a letter to the editor about their article "Activated Protein C for Sepsis" in the December 31, 2009 issue is presented.

  • Drotrecogin Alfa (Activated): A Viewpoint by Derek C. Angus. Angus, D.C. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the efficacy of drotrecogin alfa in reducing the mortality of patients with severe sepsis. Role of endogenous activated protein C in sepsis; Benefits and adverse effect of drotrecogin alfa therapy; Limited data on patient-centered outcomes associated with therapy.

  • Managing high-cost biotechnology products. Wong, Dorothy H.; Yang, Peggy // American Journal of Health-System Pharmacy;6/15/2003, Vol. 60 Issue 12, p1213 

    Offers ways to ensure the appropriate use of Drotrecogin alfa, a recombinant human activated protein C with U.S. Food and Drug Administration-approved labeling for use in the treatment of severe sepsis in adult. Medication-related issues; Criteria for use; Medication-use evaluation to track...

  • Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores, S.M. // Postgraduate Medical Journal;Jan2003, Vol. 79 Issue 927, p5 

    Recent studies have highlighted the close link between activation of the coagulation system and the inflammatory response in the pathophysiology of severe sepsis. The protein C anticoagulant pathway plays an integral part in modulating the coagulation and inflammatory responses to infection. In...

  • P & T PORTFOLIO.  // Drug Topics;2/18/2002, Vol. 146 Issue 4, p16 

    Evaluates the recombinant form of human protein C, Drotrecogin alfa for reducing mortality in adult patients with severe sepsis. Efficacy of the drug; Pharmacology; Warnings related to use.

  • Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi. Levi, M. // Drugs;2002, Vol. 62 Issue 4, p631 

    Examines the therapeutic use of protein C in the treatment of sepsis. Role of microvascular thrombosis in organ failure and mortality in patients with sepsis; Beneficial effect of activated protein C; Strategies to reduce mortality from sepsis.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics